Seqirus’ Next Generation Cell-based Influenza Vaccine Shows Significantly Greater Effectiveness Compared to Standard Egg-based Options in the 2017-18 US Influenza Season
| | | |

Seqirus’ Next Generation Cell-based Influenza Vaccine Shows Significantly Greater Effectiveness Compared to Standard Egg-based Options in the 2017-18 US Influenza Season

On Dec. 5, 2018, Seqirus, a CSL subsidiary, announced real-world data showing that its cell-based quadrivalent influenza vaccine…